The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...

Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...

Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...

Addiction risks from opioid drugs come from their targeting of receptors found primarily in the central nervous system. Other pathways are associated with pain, but many research efforts to hit them ...

Thomas Kleyman, MD, professor of medicine and chief of the renal-electrolyte division at the University of Pittsburgh Medical Center, is a senior author of the study. Sodium channels found outside the ...

Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nature Communications a high-speed atomic force microscopy study of the structural dynamics of sodium ion ...